All sponsors

AbbVie $ABBV

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS136
PHASE 3 / 2-374
RECRUITING61
READOUTS ≤12 MONTHS37
READOUT SLIPPED >6 MO46%

Delay Index: of 105 active trials registered more than a year ago, 48 have moved their primary completion (readout) date by more than 6 months since first registration (median +4.0 months). See all sponsors →

Open AbbVie on the live radar map → 📅 $ABBV readout calendar (.ics)
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
SELECT-COMPARE
NCT02629159
P3Active, not recruitingRheumatoid Arthritis16292017-10-27 (+3 mo)
KEEPsAKE2
NCT03671148
P3Active, not recruitingPsoriatic Arthritis (PsA)4442020-06-22 (-7 mo)
KEEPsAKE 1
NCT03675308
P3Active, not recruitingPsoriatic Arthritis9642020-10-08 (-3 mo)
AD Up
NCT03568318
P3Active, not recruitingAtopic Dermatitis15332021-02-16 (+14 mo)
Viale-a
NCT02993523
P3Active, not recruitingAcute Myeloid Leukemia (AML)4432021-12-01 (+22 mo)
IMGN632
NCT03386513
P1/2Active, not recruitingBlastic Plasmacytoid Dendritic Cell Neoplasm; Myeloproliferative Neoplasm1792024-10-02 (+50 mo)
TRANSFORM-2
NCT04468984
P3Active, not recruitingMyelofibrosis (MF)3302025-01-29 (+35 mo)
TNB-383B
NCT03933735
P1/2Active, not recruitingMultiple Myeloma2202026-05 (+62 mo)
ATO MM
NCT06806293
P3Active, not recruitingMenstrual Migraine (MM)4682026-06-29 (-8 mo)
Telisotuzumab vedotin
NCT03539536
P2Active, not recruitingNon-small Cell Lung Cancer2702026-07 (+56 mo)
Mirvetuximab Soravtansine
NCT06682988
P2RecruitingAdvanced High-Grade Epithelial Ovarian Cancer; Primary Peritoneal Cancer1102026-07 (-21 mo)
Pomalidomide
NCT03539744
P3Active, not recruitingMultiple Myeloma2652026-08 (+67 mo)
Adalimumab
NCT06100744
P3RecruitingJuvenile Psoriatic Arthritis402026-09
ASCENT
NCT05407636
P3Active, not recruitingAMD; nAMD7352026-10 (+30 mo)
AGN-151586
NCT07730554
P2Active, not recruitingForehead Lines842026-10
AAVIATE
NCT04514653
P2Active, not recruitingNeovascular Age-Related Macular Degeneration (nAMD)1462026-10-13 (+68 mo)
ABBV-932
NCT06846320
P2RecruitingGeneralized Anxiety Disorder (GAD)3152026-11
Mirvetuximab soravtansine
NCT05456685
P2Active, not recruitingHigh Grade Ovarian Cancer; Primary Peritoneal Cancer1252026-11 (+28 mo)
LIVIGNO-1
NCT05822752
P2Active, not recruitingHepatocellular Carcinoma1302026-11 (-2 mo)
ReVenG
NCT04895436
P2RecruitingChronic Lymphocytic Leukemia (CLL)752026-11 (+27 mo)
Switch-Up
NCT06389136
P3Active, not recruitingAtopic Dermatitis1842026-11 (+14 mo)
Intrepid
NCT06468228
P3Active, not recruitingHidradenitis Suppurativa14002026-12
ATMOSPHERE
NCT04704921
P2/3Active, not recruitingAMD; nAMD6712026-12 (+45 mo)
ABBV-400
NCT06107413
P2Active, not recruitingUnresectable Metastatic Colorectal Cancer2802026-12 (+2 mo)
Start Up Japan
NCT06701331
P3Active, not recruitingAtopic Dermatitis992027-01
LIVIGNO-2
NCT06109272
P2/3Active, not recruitingHepatocellular Carcinoma892027-01 (-42 mo)
Lutikizumab
NCT06972446
P2RecruitingRheumatoid Arthritis1802027-02
Mirvetuximab Soravtansine
NCT06365853
P2Active, not recruitingRecurrent Ovarian Cancer; Folate Receptor-Alpha Positive1082027-02 (+8 mo)
Lutikizumab
NCT06524635
P2RecruitingHidradenitis Suppurativa; Atopic Dermatitis602027-02
Azacitidine
NCT04086264
P1/2Active, not recruitingAcute Myeloid Leukemia2182027-02 (+56 mo)
AURORA
NCT06602479
P2Active, not recruitingMigraine3092027-02 (+5 mo)
SELECT-SLE
NCT05843643
P3Active, not recruitingSystemic Lupus Erythematosus10142027-03 (+5 mo)
LIVIGNO-3
NCT06632951
P2Active, not recruitingUrothelial Carcinoma1502027-03 (-17 mo)
ABBV-932
NCT07220460
P2Active, not recruitingBipolar I or II Disorder842027-03 (-1 mo)
3112 Ped BPD
NCT04777357
P3RecruitingDepression; Bipolar I Disorder3802027-03 (+37 mo)
AFFIRM
NCT06063967
P3Active, not recruitingCrohn's Disease2892027-03 (+11 mo)
GLORIOSA
NCT05445778
P3Active, not recruitingOvarian Cancer; Peritoneal Cancer5202027-04 (+1 mo)
EMBARK
NCT06718101
P2Active, not recruitingAtopic Dermatitis832027-05
Ubro Peds
NCT05125302
P3RecruitingMigraine10592027-05 (+15 mo)
Carfilzomib
NCT02899052
P2Active, not recruitingMultiple Myeloma1202027-06 (+87 mo)
U-ACTIVATE
NCT03006068
P3Active, not recruitingUlcerative Colitis (UC)9502027-07 (+6 mo)
Verona
NCT04401748
P3Active, not recruitingMyelodysplastic Syndrome (MDS)5312027-07 (+29 mo)
ELARIS EM-COC
NCT04333576
P3Active, not recruitingEndometriosis8002027-07 (+34 mo)
Telisotuzumab Adizutecan
NCT06614192
P2Active, not recruitingMetastatic Colorectal Cancer742027-08 (-20 mo)
REVAMP
NCT06880744
P3Active, not recruitingUlcerative Colitis5732027-08 (-13 mo)
Venetoclax
NCT03844048
P3Active, not recruitingChronic Lymphocytic Leukemia; Acute Myeloid Leukemia1652027-08 (+31 mo)
U-ENDURE
NCT03345823
P3Active, not recruitingCrohn's Disease7472027-09 (+103 mo)
Lutikizumab
NCT06257875
P2Active, not recruitingUlcerative Colitis1562027-09 (+4 mo)
Armour Thyroid
NCT06345339
P2/3Active, not recruitingHypothyroidism27012027-09 (-9 mo)
Icalcaprant
NCT07276997
P2RecruitingMajor Depressive Disorder1952027-09
Telisotuzumab Adizutecan
NCT06772623
P1/2RecruitingNon Small Cell Lung Carcinoma; c-MET2522027-11
UBRO MM
NCT06417775
P3Active, not recruitingMigraine4962027-11 (+2 mo)
Icalcaprant
NCT06696755
P2RecruitingBipolar I Disorder; Bipolar II Disorder1952027-11 (+12 mo)
CERVINO
NCT06158841
P3Active, not recruitingMultiple Myeloma4212027-12
Lutikizumab
NCT05139602
P2Active, not recruitingHidradenitis Suppurativa2102027-12 (+49 mo)
UBRO PEDS OLE
NCT05127954
P3Enrolling by invitationMigraine12002028-01 (+8 mo)
IMGN151
NCT07024784
P2RecruitingGynecologic Cancers; Platinum-Sensitive Ovarian Cancer3772028-01
SEQUENCE
NCT04524611
P3Active, not recruitingCrohn's Disease (CD)5272028-02 (+59 mo)
Emraclidine
NCT07145918
P2RecruitingSchizophrenia2682028-02
ABBV-383 (Etentamig)
NCT06158854
P1/2RecruitingImmunoglobulin Light Chain (AL) Amyloidosis762028-02 (+26 mo)
NOA HYDRATION
NCT07880756
P3RecruitingSkin Quality1502028-02
Telisotuzumab Vedotin
NCT06568939
P2RecruitingNon-Small Cell Lung Cancer; c-MET1502028-02
Venetoclax
NCT06428019
P3RecruitingChronic Lymphocytic Leukemia1702028-03 (+16 mo)
Viti-Up
NCT06118411
P3Active, not recruitingVitiligo6142028-03 (+28 mo)
ABBV-295
NCT07752979
P2RecruitingObesity; Overweight3602028-03
Atogepant
NCT05711394
P3RecruitingEpisodic Migraine4502028-03
AndroMETa-CRC
NCT06820463
P2RecruitingMetastatic Colorectal Cancer3902028-03
OptIMMize-2
NCT04862286
P3Active, not recruitingPsoriasis1322028-04 (-20 mo)
TrenibotulinumtoxinE and OnabotulinumtoxinA
NCT07871513
P2RecruitingUpper Facial Lines; Glabellar Lines3002028-06
NAAVIGATE
NCT07592273
P2/3RecruitingDiabetic Retinopathy5762028-06
Venetoclax
NCT07387471
P2Active, not recruitingWaldenstrom Macroglobulinemia; Lymphoplasmacytic Lymphoma142028-07
U-ASTOUND
NCT05782907
P3Active, not recruitingUlcerative Colitis1222028-08
Step-Up HS
NCT05889182
P3Active, not recruitingHidradenitis Suppurativa13282028-08 (+33 mo)
NOA LIFT
NCT07794878
P3RecruitingNasolabial Folds2882028-08
SELECT-TAK
NCT04161898
P3Active, not recruitingTakayasu Arteritis (TAK)562028-08 (+73 mo)
COMMAND
NCT03398135
P3Active, not recruitingUlcerative Colitis (UC)12422028-09 (+73 mo)
AGN-151607-DP
NCT07226791
P2RecruitingVentral Hernia2002028-09
Telisotuzumab Adizutecan
NCT07769502
P2RecruitingPancreatobiliary Cancers; Pancreatic Ductal Adenocarcinoma1682028-09
XEN63 Glaucoma Treatment System
NCT06822738
P3RecruitingPrimary Open Angle Glaucoma1302028-11
AGN-151607-DP
NCT07673107
P2RecruitingUpper Limb Essential Tremor942028-11
RGX-314 SRLTFU
NCT03999801
P2Enrolling by invitationNeovascular Age-related Macular Degeneration; Wet Macular Degeneration8652028-12
Telisotuzumab Vedotin
NCT04928846
P3RecruitingNon Small Cell Lung Cancer; c-MET7682028-12 (+21 mo)
Risankizumab
NCT07933536
P2Not yet recruitingModerate to Severe Psoriasis1052028-12
FLORENZA
NCT07059845
P2RecruitingOvarian Cancer4002029-01
FORTIFY
NCT03105102
P3Active, not recruitingCrohn's Disease13362029-02 (+106 mo)
Jump Up AA JP
NCT07023302
P3Active, not recruitingAlopecia Areata1252029-02
RISE
NCT05995353
P3RecruitingCrohn's Disease1102029-04
AGN-193408 SR
NCT04499248
P1/2Active, not recruitingOpen-angle Glaucoma; Ocular Hypertension1002029-04 (+59 mo)
SEZanne
NCT07155174
P2RecruitingSmall Cell Lung Cancer1802029-04 (-29 mo)
AndroMETa-CRC
NCT07525206
P3RecruitingColorectal Cancer9902029-05
SELECT-sJIA
NCT05609630
P3RecruitingJuvenile Idiopathic Arthritis902029-06 (+32 mo)
NOA VOLUME
NCT06734351
P3RecruitingMid Face Volume Deficit2312029-07 (+9 mo)
ABBV-722
NCT07904754
P2Not yet recruitingRheumatoid Arthritis2502029-07
Lutikizumab
NCT06865105
P2RecruitingPsoriatic Arthritis3002029-08 (+19 mo)
ABBV-142
NCT07230288
P2RecruitingIdiopathic Pulmonary Fibrosis1652029-09
ABBV-6628
NCT07160179
P1/2RecruitingGeographic Atrophy; Age-Related Macular Degeneration662029-10
Telisotuzumab Adizutecan
NCT07744126
P2RecruitingHead and Neck Squamous Cell Carcinoma1502029-10
Telisotuzumab Adizutecan
NCT07023289
P2RecruitingColorectal Cancer1402029-11
ELAPR002f Injectable Gel
NCT07207369
P3RecruitingAcne Scars3952029-11
Start Up
NCT06461897
P3Active, not recruitingAtopic Dermatitis6992029-11 (+26 mo)
ABBV-1480
NCT07756645
P3RecruitingNon-Small Cell Lung Cancer9402029-12
Target CD
NCT06548542
P2RecruitingCrohn's Disease5902030-01 (+25 mo)
Carboplatin
NCT06890338
P2RecruitingEpithelial Ovarian Cancer; Fallopian Tube Cancer1402030-02 (+4 mo)
Telisotuzumab Adizutecan
NCT07821684
P3Not yet recruitingNon-Squamous Non-Small Cell Lung Cancer6602030-03
Up-AA
NCT06012240
P3RecruitingAlopecia Areata15002030-04 (+58 mo)
ABBV-706
NCT07365241
P3RecruitingSmall Cell Lung Cancer5312030-09
Telisotuzumab Adizutecan
NCT07155187
P2/3RecruitingNon-Small Cell Lung Cancer; c-MET4902030-09 (-11 mo)
ABBV-1758
NCT07599670
P1/2RecruitingAlzheimer's Disease2102030-10
AndroMETa-GEA
NCT06628310
P2Active, not recruitingLocally Advanced Unresectable or Metastatic Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma1852030-10
Surzetoclax
NCT06953960
P1/2RecruitingMultiple Myeloma3252030-12
Telisotuzumab Adizutecan
NCT07196644
P2RecruitingSolid Tumors Harboring MET Amplification1002030-12
Venetoclax
NCT02966756
P2Active, not recruitingChronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL)662030-12
U-EMPOWER
NCT06332534
P3Active, not recruitingCrohn's Disease1112031-01 (-15 mo)
ARTIA Reconstructive Tissue Matrix
NCT06575192
P3RecruitingBreast Reconstruction2642031-02 (+14 mo)
Atogepant
NCT06810505
P3RecruitingChronic Migraine4202031-03
Dexamethasone
NCT03314181
P2Active, not recruitingMultiple Myeloma1562031-05
Standard of Care
NCT05296447
P2Active, not recruitingDiabetic Retinopathy, DR1032031-06 (+40 mo)
Telisotuzumab adizutecan
NCT07490301
P2/3RecruitingMetastatic Pancreatic Ductal Adenocarcinoma; PDAC9002031-06
Standard of Care
NCT05210803
P2Enrolling by invitationNeovascular Age-Related Macular Degeneration (nAMD)1162031-07 (+54 mo)
ABBV-706
NCT07895056
P2Not yet recruitingExtensive Stage-Small Cell Lung Cancer802031-08
Risankizumab
NCT07697456
P2RecruitingCrohn's Disease; Ulcerative Colitis20002031-10
LIVIGNO-4
NCT06236438
P2/3Active, not recruitingNon-Small Cell Lung Cancer1672031-10
Alveltamig
NCT07895043
P2Not yet recruitingExtensive Stage-Small Cell Lung Cancer (ES-SCLC)802031-12
Upadacitinib
NCT07772492
P3RecruitingSevere Alopecia Areata3002032-03
Kaleidoscope
NCT05707949
P3Enrolling by invitationMigraine Prophylaxis6502032-04 (+33 mo)
REVIVAL
NCT07581002
P2/3RecruitingAcute Myeloid Leukemia6602032-06
Ph3 Peds Viti
NCT07896434
P3Not yet recruitingNon-Segmental Vitiligo1542032-08
25mg Eluxadoline
NCT04880876
P3Enrolling by invitationIrritable Bowel Syndrome1242032-12 (+60 mo)
Etentamig
NCT07728188
P3RecruitingRelapsed or Refractory Multiple Myeloma5202033-02
Surabgene Lomparvovec (ABBV-RGX-314)
NCT07007065
P3RecruitingNeovascular Age-related Macular Degeneration5612033-03
MIGHTY
NCT07071519
P3RecruitingUlcerative Colitis1202034-07
Etentamig
NCT07793422
P3Not yet recruitingAmyloid Light Chain (AL) Amyloidosis3702034-12
ABBV-722
NCT07933211
P2/3Not yet recruitingSystemic Sclerosis5802035-06
Etentamig
NCT06892522
P1/2RecruitingMultiple Myeloma6022035-12 (-3 mo)
Standard of Care
NCT07005102
P2/3RecruitingNon-Squamous Non-Small Cell Lung Cancer; c-MET8542036-11 (+59 mo)
Etentamig
NCT07095452
P2/3RecruitingMultiple Myeloma6802041-03 (-10 mo)